RxDoctor Payments Data

Susan Castronuovo, MD

Ophthalmology · Schenectady, NYNPI 1235314527

Payments from drug & device makers

$1,575in general payments, 2019–2025

Across 53 payments — averaging $29.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Apellis Pharmaceuticals, Inc.$232
  • Sun Pharmaceutical Industries Inc.$212
  • Astellas Pharma US Inc$179
  • Novartis$142
  • AbbVie$129
  • Mallinckrodt Enterprises LLC$120
  • plus $560 from 13 others

What the payments were for

  • Food & beverage$1,575100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,575 in reported general payments places this provider in the 50th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$121,880
Medicare patients
742
Services billed
1,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast48$87,585
RestasisCyclosporine40$51,842
CequaCyclosporine25$21,371
Cyclosporine51$13,373
RocklatanNetarsudil Mesylat/Latanoprost34$11,427
Brimonidine Tartrate25$2,683
Latanoprost184$1,725
ErythromycinErythromycin Base108$1,382
Tobramycin-DexamethasoneTobramycin/Dexamethasone17$623
Dorzolamide Hcl11$280
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat15$237
Timolol Maleate27$210
Ofloxacin13$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$22$87,58548 claims
AbbVieRestasis$129$51,84240 claims
Sun Pharmaceutical Industries Inc.Cequa$212$21,37125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →